FLT

DRUG4 trials

Sponsors

Stanford University, National Cancer Institute (NCI), Jonsson Comprehensive Cancer Center, University of Oklahoma

Conditions

Acute Lymphocytic LeukemiaAcute Myeloid LeukemiaAmbiguous Lineage Leukemia or LymphomaLarge B Cell Diffuse LymphomaLymphomaLymphoma, Non-HodgkinMyelomaPancreatic Cancer

Phase 1

Pilot Imaging Study of Leukemia

RecruitingNCT03633955

University of OklahomaAcute Lymphocytic Leukemia, Acute Myeloid Leukemia, Ambiguous Lineage Leukemia or Lymphoma +1

Start: 2023-01-19End: 2028-04-01Target: 60Updated: 2026-03-05

Phase 2

A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC

CompletedNCT00963807

National Cancer Institute (NCI)Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma +3

Start: 2009-09-30End: 2014-11-30Updated: 2017-03-17

Unknown Phase

Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx

CompletedNCT00767273

Stanford UniversityPancreatic Cancer

Start: 2006-10-31End: 2007-12-31Target: 30Updated: 2012-06-11

FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma

CompletedNCT01410630

Jonsson Comprehensive Cancer CenterLarge B Cell Diffuse Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin

Start: 2017-09-07End: 2019-10-04Updated: 2021-05-11